Logbook for Fabrazyme® Home Infusion

Version 1.0 May 2021



This additional risk minimization are approved by SFDA

Contact details (to be completed by treating physician)

Emergency Number:

Patient

| Name: | |
|-------------|--|
| Birth Date: | |
| Address: | |
| Zip / City: | |
| Telephone: | |

Patient's Caregiver

| Name: | |
|-------------|--|
| Address: | |
| Zip / City: | |
| Telephone: | |

Pharmacy Name: Address:

| Address: | |
|-------------|--|
| Zip / City: | |
| Telephone: | |

Treating physicianName:Hospital:Address:Zip / City:Telephone:Emergency:

| Nurse | |
|---------------|--|
| Name: | |
| Organisation: | |
| Address: | |
| Zip / City: | |
| Telephone: | |

Administration details (to be completed by treating physician)

| Fabrazyme administered since: | (DD-MM-YYYY): |
|-------------------------------|---------------|
| First infusion at home: | (DD-MM-YYYY): |

| Fabrazyme dosing regimen | |
|--|--|
| Dose: | |
| Frequency: | |
| Rate of infusion: | |
| Required reconstituted volume (ml): | |
| Total volume in infusion bag (ml): | |
| Pre-treatment medication: (if applicable) | |
| Reasons for Fabrazyme infusion at home: | |
| Findings and actions from the initial interview: | |
| Indicate support to be provided by infusion nurse at home: | |

Necessary actions in the event of a serious infusion-associated reaction

(to be completed by treating physician)

| 1. Stop the infusion | |
|---------------------------------------|-----|
| 2. Call the national emergency number | |
| Telephone number: | 997 |
| 3. Call the physician | |
| Telephone number: | |
| Telephone number (24hr): | |
| Name of physician: | |
| Name of clinic: | |
| Total volume in infusion bag (ml): | |
| Address: | |
| | |

| 4. Emergency medication | |
|-----------------------------|--|
| Medication, including dose: | |
| | |

5. Patient's contact person to be notified

| Name: | |
|------------|--|
| Telephone: | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

- The patient and/or caregiver(s) have been informed about the associated risks of home infusion of Fabrazyme, and proper education on the use of emergency medications has been provided.
- In the event of any infusion-associated reaction, the infusion must be immediately discontinued
- Necessary actions in the event of a serious infusion-associated reaction, including emergency contact details, are described in the Logbook. Keep this information readily available during the infusion procedure.

Dose

| Required reconstituted volume (ml): | |
|--|-------------|
| Number of vials used: | 5mg vials: |
| | 35mg vials: |
| Duration of administration: | |
| Rate of administration: | |
| Problems/Remarks related to the infusion, if any (including infusion- associated reaction(s), action taken, and outcome): | |
| Patient's general health status - Describe any new health issues that you are currently experiencing prior to infusion, if any: | |

| Date of infusion: | (DD-MM-YYYY): |
|--------------------------------------|---------------|
| Nurse: | |
| Caregiver (if different from above): | |

Notes

Notes

For Medical Information, please contact: +966-12-6693318 E-mail: ksa.medicalinformation@sanofi.com

In case of any drug related adverse events, please contact: The National Pharmacovigilance Center (NPC):

Fax: +966-11-205-7662 Call Center: 19999 E-mail: npc.drug@sfda.gov.sa Website: h ps://ade.sfda.gov.sa

For SANOFI Pharmacovigilance center, please contact: +966-544-284-797 E-mail: Ksa_pharmacovigilance@sanofi.com

For extra copies please contact: +966 564095207



